Adicet Bio, Inc.

Canaccord Genuity Acted as a Co-Manager in a Follow-On Offering for Adicet Bio, Inc.

Transaction Overview:

Adicet Bio, Inc. (the “Company”) (Nasdaq:ACET), priced its $120.0 million public offering on February 10, 2021 at a price of $13.00 per share. The Company issued 9,230,770 shares of common stock. The Underwriters exercised their option to purchase an additional 1,344,743 shares of common stock at a public offering price, bringing the total proceeds to $137.5 million, less the underwriting discounts and commissions.

Company Overview:

Adicet Bio, Inc. is a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients.